Halozyme Therapeutics (HALO) –
-
Form 4 HALOZYME THERAPEUTICS, For: Apr 16 Filed by: LaBarre Michael J.
-
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
-
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
-
Form 4 HALOZYME THERAPEUTICS, For: Mar 26 Filed by: LaBarre Michael J.
-
Form ARS HALOZYME THERAPEUTICS, For: Dec 31
-
Form DEFA14A HALOZYME THERAPEUTICS,
-
Form DEF 14A HALOZYME THERAPEUTICS, For: Dec 31
-
Form 4 HALOZYME THERAPEUTICS, For: Mar 12 Filed by: LaBarre Michael J.
-
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
-
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
-
Form PRE 14A HALOZYME THERAPEUTICS, For: Dec 31
-
TD Cowen Starts Halozyme Therapeutics (HALO) at Outperform, 'I Can See Your Halo…But I Never Really Had A Doubt'
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 27 Filed by: LaBarre Michael J.
-
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 23 Filed by: LaBarre Michael J.
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 23 Filed by: Snyder Mark Howard
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 23 Filed by: LaBrosse Nicole
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 23 Filed by: Torley Helen
-
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
-
Halozyme to Participate in Upcoming Investor Conferences
-
Halozyme Therapeutics (HALO) PT Raised to $50 at H.C. Wainwright
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 16 Filed by: LaBarre Michael J.
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 16 Filed by: Snyder Mark Howard
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 16 Filed by: LaBrosse Nicole
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 16 Filed by: Torley Helen
-
Form 10-K HALOZYME THERAPEUTICS, For: Dec 31
-
Form 8-K HALOZYME THERAPEUTICS, For: Feb 20
-
Halozyme Therapeutics (HALO) Tops Q4 EPS by 2c ; Offers Guidance
-
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 15 Filed by: LaBarre Michael J.
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 15 Filed by: LaBrosse Nicole
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 15 Filed by: Torley Helen
-
Form SC 13G/A HALOZYME THERAPEUTICS, Filed by: VANGUARD GROUP INC
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 10 Filed by: LaBarre Michael J.
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 10 Filed by: LaBrosse Nicole
-
Form 4 HALOZYME THERAPEUTICS, For: Feb 10 Filed by: Torley Helen
-
Form SC 13G/A HALOZYME THERAPEUTICS, Filed by: Artisan Partners Limited Partnership
-
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
-
Form SC 13G/A HALOZYME THERAPEUTICS, Filed by: Invesco Ltd.
-
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Form SC 13G/A HALOZYME THERAPEUTICS, Filed by: BlackRock Inc.
-
Form 4 HALOZYME THERAPEUTICS, For: Jan 16 Filed by: LaBarre Michael J.
-
Halozyme (HALO) Announces argenx Received Approval in Japan for VYVDURA Co-Formulated with ENHANZE for gMG
-
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
-
Halozyme Therapeutics (HALO) PT Lowered to $48 at Wells Fargo
-
Halozyme Therapeutics (HALO) PT Lowered to $48 at H.C. Wainwright
-
Halozyme Therapeutics (HALO) PT Lowered to $40 at Goldman Sachs
-
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBarre Michael J.
-
Halozyme Therapeutics (HALO) Issues FY23 Guidance
-
Form 8-K HALOZYME THERAPEUTICS, For: Jan 17
Back to HALO Stock Lookup
